If a doctor told you that you have a fatty liver, you probably also heard the whole treatment plan in one sentence: lose some weight. For decades that was genuinely all there was. In March 2024 the first medicine was approved. In August 2025 a second one followed, a drug millions of people already take for weight loss. And the most closely watched studies in liver medicine are now testing whether the next generation can stop this disease before it turns into cirrhosis.
Can a medicine stop fatty liver from becoming cirrhosis?
The study designed to answer that is recruiting now, at sites in Florida, Louisiana, New York, Texas, and Utah.
What fatty liver disease is
Fatty liver disease means fat has built up inside liver cells. In 2023 the medical world renamed it: nonalcoholic fatty liver disease (NAFLD) became metabolic dysfunction associated steatotic liver disease, or MASLD, and its aggressive form, NASH, became MASH. The new names drop the word "alcoholic" and point to the real cause: the same metabolic problems behind type 2 diabetes and obesity. You will still hear all four names, and they mean the same things.
It is far more common than most people realize. About 38 percent of adults worldwide have it, and roughly 1 in 3 American adults. Among people with type 2 diabetes the figure is about 70 percent, and among people with prediabetes it is between 37 and 50 percent. Most have no idea. The liver tissue itself has almost no pain nerves, so it can carry fat and even scarring for years without a single symptom. Many people find out from a routine blood test or an ultrasound ordered for something else.
Simple fat is not the danger. The danger is what happens in about 1 in 5 of those people: the fat triggers inflammation (that is MASH), the inflammation causes scarring, and over 10 to 20 years the scarring can become cirrhosis. MASH is now among the leading reasons for liver transplants in the US and the fastest growing cause of liver cancer. And it is moving in the wrong direction for the people at highest risk: a 2025 analysis of national health data found that among American adults with diabetes, significant liver scarring reached 27 percent and cirrhosis 10 percent, and both are still rising.
Step one is still weight loss, and here is what the numbers actually say
Every guideline starts here, and for good reason: it works, if it happens. The clearest evidence comes from a study that followed people with fatty liver disease with repeat biopsies after a year of lifestyle change. The results were remarkably dose dependent:
- 3 to 5 percent weight loss reduced liver fat.
- Around 7 percent calmed the inflammation. Steatohepatitis resolved in most people who got there.
- 10 percent or more was the threshold for scarring: 45 percent of those people saw their fibrosis regress, and nobody in that group got worse.
The same study delivered the uncomfortable part. Only about 1 in 10 participants managed to lose 10 percent through diet and exercise alone. Most people, trying hard, landed at 3 to 5 percent. That gap, between what works and what is achievable, is the single biggest reason the field spent 40 years searching for a medicine.
What the lifestyle advice looks like in practice: a Mediterranean style eating pattern (more vegetables, fish, olive oil, nuts, less sugar and processed food), 150 to 200 minutes of moderate exercise per week plus some resistance training, and, if you have scarring, no alcohol. If you drink coffee, keep drinking it: several large studies have linked regular coffee consumption to less liver scarring, though nobody has proven that starting to drink it helps. For a deeper look at the weight loss side, our guide to obesity treatment options covers what is approved and what is being studied.
The first medicine: resmetirom (Rezdiffra), March 2024
Rezdiffra is a once daily pill that switches on a thyroid hormone receptor found mainly in the liver, which speeds up how the liver burns fat. In its Phase 3 trial, about 900 people with MASH and moderate to advanced scarring took the drug or a placebo for a year, then had a second biopsy. MASH resolved in 26 to 30 percent of people on Rezdiffra versus 10 percent on placebo. Scarring improved by at least one stage in 24 to 26 percent versus 14 percent on placebo.
Put another way: roughly 1 in 6 people benefited beyond what placebo alone would give. That is a real effect and a modest one, and it is why the approval was called a starting point rather than a finish line. The most common side effects were diarrhea and nausea. It is approved for adults with MASH and F2 to F3 fibrosis, not for people with cirrhosis and not for people with fat but no scarring.
The second: semaglutide (Wegovy), August 2025
You know this one. Semaglutide is the GLP-1 medicine sold as Wegovy for weight loss and Ozempic for diabetes. On August 15, 2025, the FDA approved Wegovy for MASH with moderate to advanced fibrosis, making it the first GLP-1 medicine ever approved for the liver.
The evidence came from the ESSENCE trial. After 72 weeks, scarring improved without the disease getting worse in 37 percent of people on Wegovy versus 22.5 percent on placebo. MASH resolved in 62.9 percent versus 34.1 percent. Those are stronger numbers than Rezdiffra's, though the two trials differed in length and design, so a direct comparison is not fair. The likely reason it works is not mysterious: people on it lose a lot of weight, and weight loss is what the liver responds to, though researchers suspect there is a direct effect on liver inflammation too.
Both approvals share an important asterisk. They were granted under the FDA's accelerated pathway, based on biopsy changes at one to two years. Neither drug has yet proven that it prevents what patients actually fear: cirrhosis, liver failure, transplant, or liver cancer. Studies to demonstrate that, called outcomes trials, are still running for both.
What about Zepbound and Mounjaro?
This is the question most people with fatty liver and a GLP-1 prescription are asking. Tirzepatide, the medicine in Zepbound (for weight loss) and Mounjaro (for diabetes), works on two hormone receptors instead of one and typically produces more weight loss than semaglutide. Its liver data so far comes from a Phase 2 trial published in 2024: after a year, MASH resolved in 62 percent of people on the highest dose versus 10 percent on placebo. Scarring improved in about half of treated participants versus 30 percent on placebo, a difference that looked promising but did not reach statistical significance in that smaller study.
Tirzepatide is not approved for the liver. Doctors can prescribe it for weight or diabetes, and many people with fatty liver take it for those reasons, but whether it protects the liver in the long run is unproven. That is precisely what the largest trial in this field is now testing.
The next one: retatrutide
Retatrutide is an experimental medicine that works on three hormone receptors, and it has produced the largest weight loss ever seen in a trial, more than 24 percent of body weight at 48 weeks in its Phase 2 study. Its liver data comes from a substudy of 98 people with fatty liver: at the highest dose, liver fat fell by about 82 percent in 24 weeks, and 86 percent of participants ended up with a normal amount of liver fat. Placebo did nothing.
Retatrutide is not approved for anything, and no one can prescribe it. The liver fat result is striking, but fat is the easy part. The hard question, and the one that decides whether a medicine truly changes this disease, is scarring and outcomes.
The study asking the question nobody has answered yet
SYNERGY-Outcomes is one of the largest liver studies ever undertaken. It is sponsored by Eli Lilly, the maker of Mounjaro, Zepbound, and retatrutide, and one of the largest pharmaceutical companies in the world. Rather than measuring fat or biopsy changes, it asks the question that matters most: over about four years, do tirzepatide or retatrutide actually prevent serious liver outcomes, such as progression to cirrhosis and its complications, in people who already have scarring?
Who the study is for. Adults with fatty liver disease and moderate to advanced scarring, meaning liver fat of 8 percent or more and a FibroScan reading between 10 and 20 kPa. A few other things also need to be true:
- a BMI of 25 or higher
- no other liver disease, such as hepatitis or alcohol related liver disease
- no history of complications like fluid in the belly or bleeding veins
- stable weight, with no loss of more than 11 pounds in the past three months
- if you have diabetes, type 2 with an A1c of 10 or below (type 1 is not eligible)
How it works. About 4,500 participants are randomly assigned to a study medicine or placebo, given as a weekly injection, and followed for about four years. When the main study ends, there is an optional two year extension in which every participant, including those who received placebo, gets one of the active medicines.
The study is recruiting at sites in Florida, Louisiana, New York, Texas, and Utah. If your situation matches, you can check your eligibility and apply here. The study team confirms everything, including your FibroScan and blood tests, at a screening visit, and applying commits you to nothing, , and every detail is explained during informed consent before you decide.
Why this field took 40 years, and why it is moving now
The biopsy problem. Until recently, the only way to prove a drug helped was a liver biopsy before and after, read by pathologists who often disagree with each other. Trials were slow, expensive, and hard to recruit for. FibroScan and blood tests like ELF are changing that, and the newest trials, including SYNERGY-Outcomes, enroll people based on these noninvasive tests rather than a needle.
The graveyard. More than a dozen promising MASH drugs failed in late stage trials between 2015 and 2022. Several reduced fat beautifully and did nothing for scarring. The field learned that fat and fibrosis are different problems.
The metabolic turn. The breakthrough came from treating the disease as what it is: a metabolic condition that happens to show up in the liver. The medicines that work best so far are the ones that fix the metabolism, which is why the GLP-1 class moved to the center of liver research almost overnight.
The outcomes gap. Everything approved so far rests on biopsy changes. The trials now running are the first designed to show that a medicine keeps people out of the hospital and off the transplant list. That is a higher bar, and it takes years.
How to find your stage, and your study
Everything above depends on one thing you may not know yet: how much scarring you have. Fat alone, with no fibrosis, is not what the approved medicines or the big trials are for. If your doctor has only mentioned "fatty liver" on an ultrasound, the next step is a FIB-4 score, which can be calculated from routine blood tests you have likely already had, and then a FibroScan if the score is elevated. Our guide to reading FibroScan results explains what the numbers mean and where the 10 kPa line falls.
Once you know your stage, your options open up. People with F2 to F3 scarring may qualify for Rezdiffra or Wegovy through their doctor. The same group, specifically those with a FibroScan between 10 and 20 kPa and a BMI of 25 or higher, is who the SYNERGY-Outcomes study is recruiting right now, to test whether tirzepatide or retatrutide can prevent scarring from progressing to cirrhosis. If those numbers sound like yours, you can check your eligibility and apply here; the study team confirms your FibroScan and blood tests at a screening visit before anything is decided.
People at any other stage can look at research too: dozens of fatty liver studies are recruiting across the US right now, from lifestyle programs for early disease to medicine trials for advanced scarring, and you can browse all active fatty liver studies here, filtered by location. And if you have diabetes, our type 2 diabetes treatment guide covers how the newest diabetes medicines and liver research now overlap.
Common questions about fatty liver treatment
How do I reduce fatty liver quickly? There is no quick fix, but liver fat responds faster than most people expect. Cutting added sugar and refined carbohydrates, especially sugary drinks, reduces liver fat within weeks, before the scale moves much. A 3 to 5 percent weight loss measurably lowers fat. Crash diets are not recommended: rapid weight loss of more than about 3 pounds a week can temporarily worsen liver inflammation.
What is the best drink for fatty liver? Water, and then coffee. Regular coffee drinkers have less liver scarring in large observational studies, with the strongest signal at 2 to 3 cups a day, though this has not been proven in a trial. Unsweetened tea is fine. Sugary drinks and fruit juice are the worst options, because the liver turns fructose into fat directly. Alcohol should be limited, and avoided entirely if you have scarring.
What foods are good for fatty liver? The Mediterranean pattern has the best evidence: vegetables, legumes, whole grains, fish, olive oil, and nuts, with little red meat, sugar, or processed food. No single food cures fatty liver, and no supplement has been shown to reverse scarring. What matters is the overall pattern and the resulting weight change.
Is fatty liver dangerous? Simple fat with no inflammation is common and usually stable. The danger is progression: about 1 in 5 people develop MASH, and some of those progress to cirrhosis over one to two decades. People with diabetes and obesity are at the highest risk. Fatty liver also raises the risk of heart disease, which is actually the most common cause of death in people with the condition. Knowing your scarring stage is what tells you which group you are in.
Can fatty liver cause pain? Usually not, which is why it goes unnoticed. Some people feel a dull ache or fullness under the right ribs, often when the liver is enlarged, but most have no symptoms at all until scarring is advanced. Pain in that area is worth checking, but its absence says nothing about how healthy your liver is.
See Fatty Liver clinical trials recruiting now
Browse open studies, filter by location, and apply in about 5 minutes: Fatty Liver Clinical Trials